Volume Spike Investor » AMAG

Top Day Trader Alerts (AIB, AMAG, CIT, CVS, HAS, NBG)

247admin — Mon, 08 Feb 2010 13:49:04 +0000

These are this Monday morning’s top day trader and active trader alerts seen with price or volume moves.

Allied Irish Banks plc (NYSE: AIB) is seeing its ADRs trade lower yet again on concern of sovereign debt exposure in the PIIGS. Shares are down 7.5% at $3.06 in early pre-market trading.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) is up on thin volume after the company issued a statement defending its recent troubles as the same percentages as had been indicated in testing. The stock closed at $37.77 Friday and is up 5.9% at $40.00 on thin volume so far this morning.

CIT Group, Inc. (NYSE: CIT) is up 4% at $32.00 this morning after naming John Thain as CEO and Chairman of the company.

CVS Caremark Corporation (NYSE: CVS) is up 2.7% at $31.91 on over 50,000 shares after beating earnings expectations.

Hasbro Inc. (NYSE: HAS) is up after $1.09 EPS vs. $0.81 Thomson Reuters estimates. Revenue rose over 11% to $1.37 billion vs. $1.33 billion estimates. Shares are up 9% at $33.60 on almost 100,000 shares.

National Bank of Greece SA (NYSE: NBG) is seeing its ADRs down yet again over Greek debt risks and the concern in the PIIGS… Shares are down over 8% at $3.61 in early pre-market trading.

You are invited to join our free daily email distribution list to hear about top analyst upgrades and downgrades, IPOs and secondary offerings, ongoing day trader and options trader alerts, stock and market rumors, Buffett and guru investor news, M&A and more.

Price snapshots take right around 8:40 AM EST

JON C. OGG
FEBRUARY 8, 2010

Premarket Alert: AMAG Pharmaceuticals (AMAG)

247admin — Wed, 01 Jul 2009 12:00:36 +0000

AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) are up about 6 percent with more than 17,000 shares traded as of 8 a.m. Eastern this morning, after the FDA approved the company’s Feraheme drug as an iron replacement therapy for patients with chronic kidney disease.

The approval removes an overhang for the company. It first sought FDA approval for the drug in December 2007, and twice received requests for more information on it last year.

The company expects to make Feraheme available in late July. — Mike Tarsala

Massive Price/Volume Surge: AMAG PHARMA (AMAG)

247admin — Thu, 13 Nov 2008 15:09:21 +0000

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) is soaring pre-market and is one of the few winner sthis morning. The FDA has designated its resubmission to the October 2008 Complete Response letter for its New Drug Application for ferumoxytol as a complete, and as a Class 1 response. AMAG is seeking marketing approval for ferumoxytol for the treatment of patients with iron deficiency anemia in all stages of chronic kidney disease.

At 9:09 AM EST we have seen 1.13 million shares trade and the stock is up OVER 75% at $32.64. Shares were right at 52-week lows just yesterday and the 52-week trading range is $18.33 to $66.94.

Expectto see exponential stock and options volume today. Average volume is only 665,000 shares.

Jon C. Ogg
November 13, 2008